GOLDMAN SACHS GROUP INC - PHASEBIO PHARMACEUTICALS INC ownership

PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of PHASEBIO PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2021$95,000
-50.3%
30,616
-40.3%
0.00%
Q2 2021$191,000
+324.4%
51,297
+294.3%
0.00%
Q1 2021$45,000
+28.6%
13,008
+24.1%
0.00%
Q4 2020$35,000
-28.6%
10,479
-24.6%
0.00%
Q3 2020$49,000
-62.6%
13,906
-51.2%
0.00%
Q2 2020$131,000
-18.1%
28,517
-41.0%
0.00%
Q1 2020$160,000
-77.5%
48,338
-58.5%
0.00%
Q4 2019$711,000
+55.2%
116,413
+6.0%
0.00%
Q3 2019$458,000109,7990.00%
Other shareholders
PHASEBIO PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Johnson & Johnson Innovation - JJDC, Inc. 1,607,044$5,400,0000.70%
NEA Management Company, LLC 6,643,704$22,323,0000.59%
DAFNA Capital Management LLC 320,542$1,077,0000.32%
Platform Technology Partners 141,025$474,0000.23%
Parkman Healthcare Partners LLC 110,547$371,0000.10%
Rock Springs Capital Management LP 1,314,374$4,416,0000.09%
GSA CAPITAL PARTNERS LLP 140,341$472,0000.08%
SABBY MANAGEMENT, LLC 65,000$218,0000.04%
Virtu Financial LLC 28,821$97,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 127,600$429,0000.01%
View complete list of PHASEBIO PHARMACEUTICALS INC shareholders